Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

nual Health Care Conference, March 17-20, 2008, Boston,

Massachusetts

-- Lehman Brothers Eleventh Annual Global Healthcare Conference,

March 18-20, 2008, Miami, Florida

-- 8th Annual Fortis Biotechnology Conference, April 3, 2008, London,

England

-- 2008 Morgan Stanley Global Healthcare Unplugged Conference,

April 30-May 2, 2008, Key Biscayne, Florida

-- Deutsche Bank 33rd Annual Health Care Conference, May 5-7, 2008,

Boston, Massachusetts

-- Bank of America 2008 Health Care Conference, May 13-15, 2008, Las

Vegas, Nevada

-- Rodman & Renshaw 5th Annual Global Healthcare Conference, May 19-20,

2008, Monte Carlo, Monaco

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the significance of 2007 events and activities; expected 2008 events and activities; upcoming milestones, including the timing of the month-12 ESMB review of lorcaserin, and the importance of such milestones; the protocol, des
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Unraveling life’s mysteries can ... The Archer Family purchased a DNA test ... ended up with a lifetime of memories, sharing, and ... family members’ DNA genuinely brought the family closer together. ... deeper into genetic history and prior to taking the ...
(Date:7/10/2014)... Ind. , July 10, 2014 /PRNewswire/ ... its use of capnography for respiratory monitoring ... group of healthcare leaders in embracing state-of-the-art ... how effectively patients are breathing and can ... occurs. By measuring the amount of carbon ...
(Date:7/10/2014)...   Ceres, Inc . (Nasdaq: CERE ... financial results for the three months ended May 31, ... Ceres reported that the company and its customers ... season in Brazil, which concluded in June, despite dry ... areas for part of the growing season. Yields of ...
(Date:7/10/2014)... the basis of psychiatric disorders has been extremely challenging ... risk but are insufficient to cause disease. Now investigators ... Press journal Cell Stem Cell describe a ... risks interact with other risk factors or environmental exposures ... research pinpoints a genetic variant that may predispose individuals ...
Breaking Biology Technology:Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9New strategy could uncover genes at the root of psychiatric illnesses 2
... Madison, Wis. - CDW Corp. , a $6 ... Hills, Ill., has agreed to acquire the stock of Madison-based ... cash. , ,The acquisition, which has been approved by ... the end of October, subject to regulatory approvals and approval ...
... Madison, Wis. - Not everyone is a fan ... most up-to-date technology - fiber to the premises. , ... the pack with trailing-edge technology is pervasive, but ... a different calculation. , ,TDS has introduced its Symmetrical ...
... Stem Cell Bank has announced it will receive human ... , giving it 13 of the 21 stem cell lines ... of the WiCell Research Institute , which houses the ... eventually will have all 21 federally approved lines. , ,"We're ...
Cached Biology Technology:Berbee believes acquisition by CDW will make it a national IT player 2Berbee believes acquisition by CDW will make it a national IT player 3TDS believes faster DSL service will suit small businesses 2Nation's only stem cell bank will receive UC-San Francisco cell line 2
(Date:7/11/2014)... addition to the hippocampus, the marginal division of ... memory. What is the impact degree of substance ... and memory function? Yan Yu and his team, ... found, using immunofluorescence staining, that substance P receptor, ... and striatal marginal division of normal rats. Unilateral ...
(Date:7/11/2014)... type 1 can inhibit voltage-gated calcium channel, ... release. However, some scholars demonstrated that cannabinoid ... influx and increase neurotransmitter release. Dr. Yi ... to Tongji Medical College, Huazhong University of ... voltage-clamp and calcium imaging in cultured trigeminal ...
(Date:7/11/2014)... spider toxins to study the proteins that let nerve ... they have stumbled upon a biological tactic that may ... plagues in a safe and environmentally responsible way. ... lethal for one species and harmless for a closely ... specific pests without harming beneficial species like bees. A ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3
... a human hair to deliver drugs to cells or assist ... of a science fiction movie, but these scenarios may be ... Carbon nanotubes, cylindrically shaped carbon molecules with a diameter of ... of fields, such as biomedical engineering and medical chemistry. ...
... The National Institutes of Health (NIH) has awarded ... University and PATH, a Seattle-based nonprofit organization, to advance ... using patches containing tiny microneedles that dissolve into the ... address key technical issues and advance the microneedle patch ...
... Elsevier ( www.elsevier.com ) , a world-leading ... and services, today announced the launch of SciVerse ... platform that will empower the scientific community to ... search and discovery process through its marketplace and ...
Cached Biology News:Nanotechnology: A dead end for plant cells? 2NIH awards $10 million to advance microneedle patch for flu vaccination 2NIH awards $10 million to advance microneedle patch for flu vaccination 3NIH awards $10 million to advance microneedle patch for flu vaccination 4Elsevier launches SciVerse Applications beta 2Elsevier launches SciVerse Applications beta 3
Based on Silica membrane matrix beads. The kit is designed for the purification of DNA (20 bp - 100 bp) from TAE/TBE agarose gels. Run time is approximately 45 minutes....
... DNA and Gel Band Purification Kit, 100. For ... and DNA fragments (0.1-10 kb) from solution and ... DNA fragments from solution in as little as ... in 15 min.Prepacked glass fiber matrix columns provide ...
These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
Newborn Bovine Serum Heat-Inactivated...
Biology Products: